Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration‐resistant prostate cancer (CRPC)
SK Pal, J Patel, M He, B Foulk, K Kraft, DA Smirnov… - Cancer, 2018 - Wiley Online Library
BACKGROUND Two androgen receptor (AR)‐targeted therapies, enzalutamide and
abiraterone acetate plus prednisone (abiraterone), have been approved for the treatment of …
abiraterone acetate plus prednisone (abiraterone), have been approved for the treatment of …
Phase II multicenter study of enzalutamide in metastatic castration-resistant prostate cancer to identify mechanisms driving resistance
RR McKay, L Kwak, JP Crowdis, JM Sperger… - Clinical Cancer …, 2021 - AACR
Purpose: Enzalutamide is a second-generation androgen receptor (AR) inhibitor that has
improved overall survival (OS) in metastatic castration-resistant prostate cancer (CRPC) …
improved overall survival (OS) in metastatic castration-resistant prostate cancer (CRPC) …
Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer
RJ Van Soest, ES de Morrée, CF Kweldam… - European urology, 2015 - Elsevier
Abstract Treatment options for metastatic castration-resistant prostate cancer (CRPC) have
evolved with the established benefit of the novel androgen receptor (AR)-targeted agents …
evolved with the established benefit of the novel androgen receptor (AR)-targeted agents …
Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer
Primary resistance to androgen receptor (AR)–directed therapies in metastatic castration-
resistant prostate cancer (mCRPC) is poorly understood. We randomized 202 patients with …
resistant prostate cancer (mCRPC) is poorly understood. We randomized 202 patients with …
Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
N Menssouri, L Poiraudeau, C Helissey, L Bigot… - Clinical Cancer …, 2023 - AACR
Purpose: The androgen receptor axis inhibitors (ARPI; eg, enzalutamide, abiraterone
acetate) are administered in daily practice for men with metastatic castration-resistant …
acetate) are administered in daily practice for men with metastatic castration-resistant …
[HTML][HTML] Cross-resistance to abiraterone and enzalutamide in castration resistance prostate cancer cellular models is mediated by AR transcriptional reactivation
I Simon, S Perales, L Casado-Medina… - Cancers, 2021 - mdpi.com
Simple Summary Prostate cancer is the second most common cancer in males. In prostate
cancer cells, androgens bind and activate the intracellular mediator called Androgen …
cancer cells, androgens bind and activate the intracellular mediator called Androgen …
Biomarkers for predicting abiraterone treatment outcome and selecting alternative therapies in castration‐resistant prostate cancer
Approximately one‐third of patients with metastatic castration‐resistant prostate cancer
(CRPC) exhibited primary abiraterone resistance. To identify alternative treatment for …
(CRPC) exhibited primary abiraterone resistance. To identify alternative treatment for …
Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer
G Galletti, BI Leach, L Lam, ST Tagawa - Cancer treatment reviews, 2017 - Elsevier
Patients with metastatic castration-resistant prostate cancer (mCPRC) now have an
unprecedented number of approved treatment options, including chemotherapies …
unprecedented number of approved treatment options, including chemotherapies …
Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer
DD Chism, D De Silva, YE Whang - Expert review of anticancer …, 2014 - Taylor & Francis
After initial response to androgen receptor (AR) targeting drugs abiraterone or
enzalutamide, most patients develop progressive disease and therefore, castration resistant …
enzalutamide, most patients develop progressive disease and therefore, castration resistant …
Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer
C Buttigliero, M Tucci, V Bertaglia, F Vignani… - Cancer treatment …, 2015 - Elsevier
In recent years, in castration resistant prostate cancer (CRPC), several new drugs have
been approved that prolong overall survival, including enzalutamide and abiraterone, two …
been approved that prolong overall survival, including enzalutamide and abiraterone, two …
相关搜索
- mechanisms of resistance prostate cancer
- mechanisms of resistance enzalutamide in patients
- mechanisms of resistance abiraterone acetate
- abiraterone acetate prostate cancer
- abiraterone acetate enzalutamide in patients
- enzalutamide in patients prostate cancer
- mechanisms of resistance systemic therapy
- transcriptional reactivation prostate cancer
- androgen receptor prostate cancer
- systemic therapy prostate cancer
- androgen receptor acquired resistance
- transcriptional reactivation abiraterone and enzalutamide
- abiraterone acetate identification of mechanisms
- identification of mechanisms prostate cancer
- identification of mechanisms enzalutamide in patients
- abiraterone and enzalutamide prostate cancer